<DOC>
	<DOCNO>NCT01359397</DOCNO>
	<brief_summary>Background : It estimate Netherlands year approximately 900 patient gastric cancer adenocarcinoma gastro-oesophageal junction candidate chemotherapy . Randomized study compare chemotherapy versus best supportive care show survival quality life prolong chemotherapy . However , chemotherapy regimen clearly superior regard prolongation survival . Therefore , tolerability treatment ease administration ( outpatient compare inpatient ) important consideration development novel treatment schedule . Study design : This open-label , multicentre , phase II trial design evaluate efficacy safety bevacizumab combination docetaxel , oxaliplatin capecitabine chemotherapy ( B-DOC ) first-line therapy patient inoperable locally advanced recurrent and/or metastatic adenocarcinoma stomach gastro-oesophageal junction . In case HER2 positive inoperable locally advanced recurrent and/or metastatic adenocarcinoma stomach gastro-oesophageal junction trastuzumab add regimen ( B-DOCT ) . Study Endpoints : Primary endpoint Progression free survival define time measure B-DOCT study , Protocol version 3.0 date January 18 , 2011 Page 5 / 60 day registration first progression death . Secondary endpoint Toxicity Overall survival , define time registration death Response rate define percentage partial complete response Duration response define time response first progression Translational research pharmacogenomic biological factor may predict treatment response .</brief_summary>
	<brief_title>Docetaxel , Oxaliplatin , Capecitabine , Bevacizumab Trastuzumab Patients With Locally Advanced Metastatic Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable locally advanced recurrent and/or metastatic disease amenable curative therapy . 2 . Measurable disease , accord Response Evaluation Criteria Solid Tumours ( RECIST ) , assess use image technique ( CT MRI ) 3 . ECOG Performance status 0 , 1 2 ( see Appendix 2 ) 4 . Life expectancy least 3 month 5 . Male female age ≥ 18 year . 6 . Signed informed consent . 7 . Assessment HER2 status ( primary tumour metastasis ) central laboratory prior initiation study treatment ( see section 9.1 ) 8 . Able swallow retain oral medication . 9 . LVEF ≥ 50 % assess multigated radionucleotide angiography ( MUGA ) cardiac ultrasound . Any following exclude patient study : 1 . Previous chemotherapy advanced/metastatic disease ( prior perioperative chemotherapy allow least 6 month elapse completion therapy enrolment study ) . 2 . Previous radiotherapy abdomen . 3 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . 4 . Patients active ( significant uncontrolled ) gastrointestinal bleeding . 5 . Residual relevant toxicity result previous therapy ( exception alopecia ) , e.g . neurological toxicity ≥ grade 2 NCICTCAE . 6 . Creatinin clearance &lt; 50 mL/min . 7 . Neutrophil count &lt; 1.5 × 109/L , platelet count &lt; 100 × 109/L . 8 . Serum bilirubin &gt; 1.5 × upper limit normal ( ULN ) ; , AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis ) ; , alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis , &gt; 10 × ULN patient bone liver metastasis ) ; , albumin &lt; 25 g/L . 9 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 10 . History document congestive heart failure ; angina pectoris require medication ; evidence transmural myocardial infarction ECG ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia . 11 . Patients dyspnoea rest due complication advance malignancy disease , require supportive oxygen therapy . 12 . Patients receive chronic high dose corticosteroid therapy . ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) . 13 . Major surgery within 4 week start study treatment ; serious healing wound . 14 . Known hypersensitivity study drug , Chinese hamster ovary cell product murine human recombinant antibody . 15 . History clinical evidence brain metastasis . 16 . Serious uncontrolled systemic intercurrent illness , e.g . infection poorly control diabetes . 17 . Positive serum pregnancy test woman childbearing potential . 18 . Subjects reproductive potential willing use effective method contraception . 19 . Any investigational drug treatment within 4 week start study treatment . 20 . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastastic site peripherally patient recover acute toxicity ) 21 . Arterial thrombosis ; cerebrovascular accident within 6 month prior study enrolment . 22 . Therapeutic use oral coumarinderived LMWH anticoagulant NSAIDs . 23 . Continuous use immunosuppressive agent ( use corticosteroid see also # 12 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Adenoca . stomach/gastr . Junct .</keyword>
</DOC>